[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657761":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":60,"overallOfficials":11,"centralContacts":75,"locations":81,"responsibleParty":98,"collaborators":11,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":11,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":11,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":11,"overallStatus":119,"whyStopped":11,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Shanghai JMT-Bio Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of Adverse Events (AE) assessed by CTCAE v6.0",null,"Baseline through week 19",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","CARE_PROVIDER",[23,29,33,38,42,46,52,56],{"label":24,"type":25,"description":26,"interventionNames":27},"JMT206 injection group 2","EXPERIMENTAL","JMT206 injection dose 2 administered subcutaneously (SC) once a week",[28],"Drug: JMT206 injection",{"label":30,"type":25,"description":31,"interventionNames":32},"JMT206 injection group 3","JMT206 injection dose 3 administered subcutaneously (SC) once a week",[28],{"label":34,"type":25,"description":35,"interventionNames":36},"JMT206 injection + Semaglutide group 1","JMT206 injection dose 1 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.",[28,37],"Combination Product: Semaglutide injection",{"label":39,"type":25,"description":40,"interventionNames":41},"JMT206 injection + Semaglutide group 2","JMT206 injection dose 2 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.",[28,37],{"label":43,"type":25,"description":44,"interventionNames":45},"JMT206 injection + Semaglutide group 3","JMT206 injection dose 3 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased",[28,37],{"label":47,"type":48,"description":49,"interventionNames":50},"Placebo","PLACEBO_COMPARATOR","Placebo administered subcutaneously (SC) once a week",[51],"Drug: Placebo injection",{"label":53,"type":48,"description":54,"interventionNames":55},"Placebo+ Semaglutide","Placebo administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.",[37,51],{"label":57,"type":25,"description":58,"interventionNames":59},"JMT206 injection group 1","JMT206 injection dose 1 administered subcutaneously (SC) once a week",[28],[61,66,71],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":11},"DRUG","JMT206 injection","JMT206 injection administered subcutaneously (SC) once a week",[34,39,43,57,24,30],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":11},"COMBINATION_PRODUCT","Semaglutide injection","Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.",[34,39,43,53],{"type":62,"name":72,"description":73,"armGroupLabels":74,"otherNames":11},"Placebo injection","Placebo administered subcutaneously (SC) once a week.",[47,53],[76],{"name":77,"role":78,"phone":79,"phoneExt":11,"email":80},"Clinical Trials Information Group officer","CONTACT","86-0311-69085587","ctr-contact@mail.ecspc.com",[82],{"facility":83,"status":11,"city":84,"state":11,"zip":11,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Peking University People's Hospital","Beijing","China","CN",{"type":88,"coordinates":89},"Point",[90,91],116.39723,39.9075,{"lat":91,"lon":90},[94],{"name":95,"role":78,"phone":96,"phoneExt":11,"email":97},"Linong Ji","+86 13910978815","jiln@bjmu.edu.cn",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657761","phase-1-evaluate-the-safety-and-tolerability-of-multiple-doses-of-jmt206-injection-in-obese-participants-100657761",false,"NCT07840729","Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants","Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is \"Individual Patients.\" A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants","Inclusion Criteria:\n\n1. Age 18\\~65 (including threshold values), male or female participants;\n2. BMI ≥ 30 kg\u002Fm²;\n3. Weight change \\\u003C5% within the 3 months prior to screening\n4. Voluntarily sign the informed consent form before the trial..\n\nExclusion Criteria:\n\n1\\) Those known to have a history of allergy to any component or related preparations in the investigational drug and its excipients, or have severe allergic diseases or allergic constitution; 2) Participants with a history of diabetes mellitus or hypoglycemic episodes; 3) Obesity is related to medication or diseases; Or weight gain caused by non-fat content; or monogene mutationsobesity; 4) History of weight loss surgery and\u002For treatment within the past year; 5) History of severe gastrointestinal disease or gastrointestinal surgery, clinically significant gastric emptying abnormalities, or long-term use of medications directly affecting gastrointestinal motility; 6) Having comorbidities known to affect skeletal muscle proteins; 7) A history of acute or chronic pancreatitis; 8) Acute gallbladder disease within one year prior to screening; 9) Previous or family history of medullary thyroid carcinoma or type 2 endocrine adenomatosis; 10) Severe cardiovascular or cerebrovascular events within 6 months prior to screening; 11) Any type of treated or untreated malignant tumor within 5 years prior to screening; 12) History of severe mental illness; 13) Use of drugs or products that may cause weight changes within 3 months prior to screening; 14) Use of drugs or products affecting skeletal muscle synthesis within 3 months prior to screening; 15) Participants deemed otherwise unsuitable for this trial by the investigator.\n\n\\-","ALL","18 Years","65 Years",{"count":111,"type":112},90,"ESTIMATED","INTERVENTIONAL",[115],"PHASE1","Use these resources to provide understandable information about this study to patients, families, and health care providers:",[118],"Valid MeSH Conditiongs","NOT_YET_RECRUITING","2026-09-24",{"date":122,"type":123},"2026-09-25","ACTUAL",{"date":125,"type":112},"2026-10-20",{"date":127,"type":112},"2027-04-30",{"name":5,"class":6},1]